Last reviewed · How we verify
Atrovent (IPRATROPIUM)
Atrovent (IPRATROPIUM) is a small molecule anticholinergic medication developed by Boehringer Ingelheim, targeting the muscarinic acetylcholine receptor M1. It was FDA-approved in 1986 for various respiratory conditions, including allergic rhinitis, bronchitis, and chronic obstructive pulmonary disease. As an off-patent medication, Atrovent is available from multiple generic manufacturers. Key safety considerations include its potential to cause dry mouth, blurred vision, and urinary retention. Atrovent's commercial status allows for generic competition, making it a widely accessible treatment option.
At a glance
| Generic name | IPRATROPIUM |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptor M1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1986 |
Approved indications
- Allergic rhinitis
- Bronchitis
- Bronchospasm
- Chronic Obstructive Pulmonary Disease with Bronchospasms
- Chronic obstructive lung disease
- Nasal discharge
- Pulmonary emphysema
Common side effects
- Bronchitis
- COPD exacerbation
- Dyspnea
- Headache
- Dry mouth
- Taste perversion (bitter taste)
- Cough
- Rhinitis
- Upper respiratory infection
- Throat irritation
- Stomatitis
- Mouth edema
Serious adverse events
- Hypersensitivity reactions including anaphylaxis
- Paradoxical bronchospasm
- Narrow-angle glaucoma precipitation or worsening
- Glaucoma
- Urinary retention
- Bronchospasm
- Angioedema
- Laryngospasm
- Supraventricular tachycardia
- Atrial fibrillation
Key clinical trials
- Effect of Ipratropium Bromide on EILO (PHASE2)
- Magnesium Trial in Acute Asthma in Emergency Department (PHASE3)
- Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD (NA)
- Revefenacin in Acute Respiratory Insufficiency in COPD (PHASE2)
- Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations (PHASE2)
- The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome (PHASE4)
- Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease (NA)
- Treating Respiratory Emergencies in Children Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atrovent CI brief — competitive landscape report
- Atrovent updates RSS · CI watch RSS